Notice for cerliponase alfa (BioMarin Pharmaceuticals Australia Pty Ltd)
Active ingredients
cerliponase alfa
Date of review outcome
Lapse date
Type
Priority review
Indication
For the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency.
Registration date